Long-term data with idebenone on respiratory function outcomes in patients with Duchenne muscular dystrophy
Decline in respiratory function in patients with DMD starts during early teenage years and leads to early morbidity and mortality. Published evidence of efficacy for idebenone on respiratory function outcomes is currently limited to 12 months of follow-up time. Here we report data collected as retro...
Main Authors: | Servais, L, Straathof, CSM, Schara, U, Klein, A, Leinonen, M, Hasham, S, Meier, T, De Waele, L, Gordish-Dressman, H, McDonald, CM, Mayer, OH, Voit, T, Mercuri, E, Buyse, GM |
---|---|
פורמט: | Journal article |
שפה: | English |
יצא לאור: |
Elsevier
2019
|
פריטים דומים
-
Lessons Learned from Discontinued Clinical Developments in Duchenne Muscular Dystrophy
מאת: Theodora Markati, et al.
יצא לאור: (2021-11-01) -
Evidence for ACTN3 as a genetic modifier of Duchenne muscular dystrophy
מאת: Marshall W. Hogarth, et al.
יצא לאור: (2017-01-01) -
Cholesterol metabolism is a potential therapeutic target in Duchenne muscular dystrophy
מאת: Fatima Amor, et al.
יצא לאור: (2021-06-01) -
Duchenne Muscular Dystrophy
מאת: J Gordon Millichap
יצא לאור: (1989-05-01) -
Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy
מאת: Frank, DE, et al.
יצא לאור: (2020)